In a new study, it suggests that there are innovative ways of using chemotherapy which will help in extending the lives of the patients who have pancreatic cancer. Pancreatic cancer is said to be one of the most deadly cancers that are known to the world. The patients who have pancreatic cancer had not lived for a longer time on a four-drug combo on a single standard cancer drug.
The result of the research which was presented on Monday at an American Society of Clinical Oncology (ASCO) conference in Chicago has indicated that the most powerful chemotherapy treatment is called as folfirinox. This treatment shows that it is likely to become the standard of care for some patients whose pancreatic cancer is usually diagnosed early to remove by surgery.
According to the Dr Richard Schilsky, who is the ASCO’s chief medical officer said this research was an immediate practice-changing study and it is said that this is the biggest advance for pancreatic cancer in last 25 years.
After an average of 3 years of follow up in this study, there is almost 40 percent of the folifirinox patients were said to be disease free as compared to about 20 percent who had the standard drug. As per Dr Thierry Conroy, who is the lead author and also the cancer specialist at the Cancer Institute of Lorraine in Vandoeuvre-les-Nancy, France said that it is seen that nearly 2-3 of folfirinox patients were alive as compared with Gemzar patients.
According to Dr Bruce Johnson, who is the ASCO President said that both of the studies are in hope for the people with cancer which typically evades the early detection and it is den difficult to treat. He said that nearly 95 percent of patients would die due to pancreatic cancer. This situation which arises due to cancer is grim, and in the UnitedStates, it is identified as one of the two worst cancers.
The patients who are suffering from this cancer need to remove a pancreatic tumour with the help of surgery, but they still face the difficult road, as per the Labow, who is not a part of the study.
In this study, nearly 500 patients at about 77 centres which are spread across Canada and France were enrolled from spring 2012 to 2016. The study was funded by philanthropic groups present in Canada and France.